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Background: Chlamydia trachomatis is the most commonly diagnosed bacterial sexually transmitted infection in
the developed world and diagnosis rates have increased dramatically over the last decade. Repeat infections of
chlamydia are very common and may represent re-infection from an untreated partner or treatment failure. The
aim of this cohort study is to estimate the proportion of women infected with chlamydia who experience
treatment failure after treatment with 1 gram azithromycin.
Methods/design: This cohort study will follow women diagnosed with chlamydia for up to 56 days post
treatment. Women will provide weekly genital specimens for further assay. The primary outcome is the proportion
of women who are classified as having treatment failure 28, 42 or 56 days after recruitment. Comprehensive sexual
behavior data collection and the detection of Y chromosome DNA and high discriminatory chlamydial genotyping
will be used to differentiate between chlamydia re-infection and treatment failure. Azithromycin levels in high-
vaginal specimens will be measured using a validated liquid chromatography – tandem mass spectrometry method
to assess whether poor azithromycin absorption could be a cause of treatment failure. Chlamydia culture and
minimal inhibitory concentrations will be performed to further characterize the chlamydia infections.
Discussion: Distinguishing between treatment failure and re-infection is important in order to refine treatment
recommendations and focus infection control mechanisms. If a large proportion of repeat chlamydia infections are
due to antibiotic treatment failure, then international recommendations on chlamydia treatment may need to be
re-evaluated. If most are re-infections, then strategies to expedite partner treatment are necessary.
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Over 100 million men and women worldwide are
infected with chlamydia at any point in time [1]. It is the
most commonly reported bacterial sexually transmitted
infection (STI) in developed countries, with over 1.4
million cases reported in the United States in 2011 [2].
Left untreated, chlamydia can ascend from the endocervix
to the upper genital tract in women and cause pelvic
inflammatory disease (PID) which can increase the risk of
developing fallopian tube scarring, potentially leading to
ectopic pregnancy, tubal infertility and chronic pelvic pain* Correspondence: jhocking@unimelb.edu.au
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reproduction in any medium, provided the or[3-5]. In addition, genital infection in pregnant women
increases the risk of preterm delivery, can be passed on to
the baby during vaginal delivery and may result in eye and
lung infections in the new born [3,6]. Infection with geni-
tal chlamydia can also increase the risk of HIV acquisition
in both men and women, and cause epididymo-orchitis in
men [4,7].
Repeat chlamydia infections are common following
treatment. Among women who tested positive in an
Australian cohort of 1116 young women who were
treated at recruitment, 18% tested positive again at
3 months (95% CI: 8%, 34%) [8]. In the UK, a prospect-
ive cohort of 16 to 24 year old women treated for chla-
mydia in general practice, reported a repeat infection
rate of 29.9% per year (95% CI: 19.7%, 45.4%) [9]. Anotherl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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infection rate of 34% per year [10] and a recent systematic
review of chlamydia repeat infection following treatment
found that the overall median proportion testing positive
again for chlamydia was 13.9% [11].
Repeat infections are generally considered to be re-
infections through exposure to an infected partner.
However, emerging evidence suggests that treatment
failure following azithromycin may account for a sub-
stantial proportion and this has led to considerable de-
bate in the medical and scientific literature [12-16].
Among female participants in a partner treatment trial
who reported no sexual intercourse after treatment, 22
of 289 (8%; 95% CI: 5%, 11%) had persistent infection
suggestive of treatment failure at follow up [17]. Simi-
larly, the treatment failure rate in a cohort of adolescent
females was 7.9% (95% CI: 4%, 10.1%) [10]. Both of these
studies attempted to differentiate between re-infection
and treatment failure using sexual behavior question-
naires. Batteiger et al. (2010) included genotyping as a
further tool to identify re-infections, but these studies
were based on self-report of sexual behavior which may
have been unreliable.
The recommended first line treatment for uncomplicated
genital chlamydia infection in most developed countries is
a 1 gram dose of the macrolide antibiotic, azithromycin
[18-20]. Although doxycycline 100 mg twice daily for 7 days
is a second line treatment for uncomplicated chlamydia, it
is not widely used because there are concerns about
compliance given the longer duration of treatment [21]. A
meta-analysis of chlamydia treatment reported a 97% cure
rate for azithromycin and 98% for doxycycline [22]. Of the
12 trials included in the meta-analysis, 11 used culture or
immunoassay rather than the more sensitive nucleic acid
amplification tests (NAAT) to determine microbial cure at
study end [22]. Given the use of culture rather than
NAATs, it is possible that the treatment efficacies in these
trials were over-estimated [12,13,23].
Governments throughout the developed world are push-
ing for increased chlamydia testing and the Australian
government has invested in a large chlamydia screening
randomized controlled trial [24]. It is imperative, there-
fore, to rigorously investigate the adequacy of currently
recommended treatment for chlamydia. We describe here
a cohort study, the Australian Chlamydia Treatment Study
(ACTS), that aims to measure the proportion of chlamydia
infected women who fail treatment when treated with 1
gram azithromycin using advanced microbiological tech-
niques to differentiate between re-infection and treatment
failure.
Research aim
The primary aim is to estimate the proportion of
women infected with chlamydia who fail treatment with1 gram azithromycin, the most widely recommended
first line treatment for genital chlamydia infection
[18-20]. The secondary aim is to determine the role of
C. trachomatis organism load, azithromycin tissue ab-
sorption of azithromycin and antimicrobial resistance in
chlamydia treatment failure.
Methods/design
Study design and setting
This is a cohort study of women who test positive for
genital chlamydia at one of two large, publically funded
sexual health centres in Melbourne and Sydney, Australia.
Participants will be followed up for up to 56 days post
treatment and will provide weekly genital specimens for
further assay.
Duration of study
Recruitment commenced in October of 2012 and is
expected to continue until October 2014, with results
reported late 2015.
Participant eligibility
Women who are diagnosed with genital chlamydia and
who meet eligibility criteria will be invited to participate
in the study. The study is limited to women because
of their increased risk of serious chlamydia related
complications.
The inclusion criteria are:
 Female;
 Positive test for genital chlamydia using Nucleic
Acid Amplification Test polymerase chain reaction
[PCR] (performed on specimens collected from
women recruited from Sydney Sexual Health
Centre) or strand-displacement assay (performed on
specimens collection from women recruited from
Melbourne Sexual Health Centre);
 Age ≥16 years;
 Adequate English and comprehension skills to give
informed consent;
 Able to attend their recruitment clinic for follow up
and specimen collection at day 7;
 Resides in a jurisdiction serviced by one of the two
clinics and plan to stay in the jurisdiction for the
next 8 weeks.
The exclusion criteria are:
 Current infection detected as a part of a routine test
for re-infection [18];
 Concomitant infection with another bacterial STI;
 Concurrent PID;
 Self report of antibiotic use in the last 2 weeks;
 Current commercial sex work;
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post;
 Women who do not have a mobile phone;
 HIV positive status;
 Concurrent medication likely to significantly interact
with azithromycin (e.g. cyclosporine, digoxin);
 Known macrolide allergy.
Recruitment
Women who have tested positive for chlamydia will be
seen by a research nurse at a participating clinic at point
of treatment. The research nurse will explain the study to
them, assess eligibility and take informed consent. The
research nurse will collect specimens for further testing
(Table 1) and provide treatment with a single dose of 1
gram azithromycin. The nurse will observe the participant
as she takes her treatment to ensure compliance. This is
classified as the baseline visit (Day 0). All clinic visits,
pathology costs and treatment for participants and their
partners will be provided free of charge.
Primary outcome
The primary outcome is the proportion of women who
are classified as having chlamydia treatment failure follow-
ing detection of chlamydia on a self-collected high-vaginal
specimen using a polymerase chain reaction (PCR – see
below) Specimens will be collected for testing on days 28,
42 or 56 after recruitment (referred to as ‘test of cure’
specimens for the purpose of this study) according to theTable 1 Specimen collection by study timeline.
Specimen collection and testing
Day 0d 7 14 21 28
Number of swabs collected 4 2 2 2 2
Culture X
PCRa X X X X
Chlamydia organism loada X X X X X
Genotypea X X X X X
Sequencinga X X X X X
Y-chromosomea X X X X
β-globina X X X X X




Location Clinice Clinice Homef Homef Hom
aProcessed in batches throughout the course of the study.
bChlamydia PCR done in real time to report results back to participants and treat an
cIf anal sex reported.
dDay 0 = baseline or at time of recruitment.
eSwabs collected by research nurse and put immediately into the appropriate medi
fSelf-collected high-vaginal swabs.
Key: X = specimen processed for this experiment, PCR polymerase chain reaction, Aalgorithm in Figure 1. This algorithm follows a previously
described method [10] with the addition of the detection
of Y chromosome DNA and performing high discrimin-
atory chlamydial genotyping. Y chromosome DNA will be
used to validate sexual behaviour data because it can be
detected in the vagina for up to 14 days after unprotected
intercourse with a male partner [25,26]. Specimens will be
collected from participants every 7 days for Y chromo-
some detection and genotyping will be undertaken on any
chlamydia positive specimens collected on days 28, 42 or
56 after recruitment. Chlamydial genotype fingerprinting
will be performed to determine any differences in chla-
mydia strain/serovar between a participant’s baseline spe-
cimen and any repeat positive specimens detected at day
28, 42 or 56 [27]. If a woman has the same serovar present
at follow up, further testing by multilocus sequence typing
(MLST) targeting ompA and five house-keeping genes will
be undertaken [28,29]. Detection of same MLST type
without detection of Y chromosome DNA or any reports
of unprotected sex will be classified as treatment failure. If
the woman has a different serovar, it will be classified as a
re-infection. A repeat positive chlamydia diagnosis will
also be classified as a re-infection if the woman’s repeat
specimen has the same MLST type and Y chromosome is
detected or she reports unprotected sexual contact.
Study endpoint
A study participant will reach the study endpoint when
she is diagnosed with treatment failure, re-infection orIf PCR positive @ d28, 42 or 56
35 42 49 56
2 2 2 2 4-5
X
X X X
X X X X X
X X X X X
X X X X X
X X X X X




ef Homef Homef Homef Homef Clinice
y women diagnosed chlamydia positive.
um.
z absorption azithromycin absorption, d day.
Figure 1 Algorithm for classifying treatment failure.
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by a test of cure PCR conducted after 28, 42 or 56 days
follow up according to Figure 2.
Further classification of treatment failure
Treatment failure will be further classified as:
Poor azithromycin absorption: There is no vomiting or
diarrhoea reported after treatment but low levels of
azithromycin concentration are found in the vaginal
cells [30,31] and the MIC for the initial chlamydia
culture is within reported range.
Persistent chlamydia not responding to azithromycin:
Azithromycin absorption shows adequate levels of
azithromycin in the vaginal cells, the minimal
inhibitory concentration (MIC) for the initial chlamydia
culture is within reported range and the subsequent
chlamydia culture is negative [13,23,32,33].
Reduced antimicrobial susceptibility and resistance:
Some viable infectious chlamydia is present when
cultured with antibiotic series compared with cultures
with no antibiotic series. The MIC for initial chlamydia
culture is elevated compared with reported rangeFigure 2 Classification of study endpoint.[13,15,32,34,35]. Evidence of 23S rRNA gene mutation
may or may not be present.
Specimen collection and testing
Participants will be asked to return to the clinic for follow
up testing at day 7 so that the research nurse can collect
further specimens. Thereafter, weekly high-vaginal speci-
mens will be self-collected at home and mailed in a
postage-paid envelope to the study centre. Participants will
receive weekly short message service (SMS) prompts
reminding them to return specimens and questionnaires
and will be telephoned if they test chlamydia positive again
throughout the study. These women will be requested
to attend the clinic for treatment and further specimen
collection. Table 1 outlines the number of specimens
collected and the tests to be undertaken at each stage of
the study.
Chlamydia polymerase chain reaction (PCR)
Test of cure swab specimens collected on day 28, 42
and day 56 will be placed in Cobas® PCR Media (Roche
Diagnostics) and will be tested in batches on COBAS
4800 CT/NG (Roche Diagnostics). The remaining eluted
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required for further assay. For specimens collected at
other time points, swabs collected will be rotated for
30 seconds in 1 ml of phosphate buffered saline (PBS)
and stored at −80°C until further testing required. Spec-
imens will be subsequently extracted with MagNA Pure
96 (Roche Diagnostics) using 200 μl of the cellular
suspension in conjunction with the total nucleic acid
isolation kit. Eluted nucleic acid of 100 μl will be tested
as required.
Genotyping & quantification of organism load
Chlamydial fingerprinting will be conducted on specimens
that are PCR positive at baseline and at test of cure. We
will determine the organism load, identify the chlamydia
serovar(s) (genovar) of each infection through a series of
quantitative PCR assays to establish whether or not the
genotype of the chlamydia detected in those women who
have a repeat positive is the same as the type present at
baseline [27]. Initial qPCR primers and probes have been
designed to predict antigenic differences in major outer
membrane protein (MOMP) to determine the serovar as
previously described [27,36-38]. The primary chlamydia
group-specific multiplex quantitative PCR will target con-
served regions of the ompA gene specific to all chlamydia
serovar groups, including the B group (serovars B, E, D,
L1, and L2), C group (serovars A, C, H, I, J, K, and L3) or
intermediate group (serovars F and G) serovars. This assay
will enable quantification of organism load and will be
used to direct serovar-specific PCRs to determine serovars
present in the specimen, including possibility of mixed
serovars [27,39].
Chlamydia organism load in each specimen will be
quantified by comparing the crossing-threshold of each
specimen to the crossing-threshold of a standard curve
constructed by amplifying different known copy num-
bers of the ompA gene. The beta globin gene, present at
one haploid copy per nucleated cells [40], will also be
quantified using qPCR to assess specimen adequacy as
well as to measure sampling variability between partici-
pants and specimens by correlation with the number of
eukaryotic cells collected. The quantity of chlamydia
will be divided by the number of eukaryotic cells and
expressed as the number of organisms present per 100
eukaryotic cells [40].
Specimens from participants where the same serovar has
been detected at baseline and follow up will undergo
further discriminatory confirmation of relatedness using
sequencing of ompA gene, as well as five house-keeping
genes (hctB, CT058, CT144, CT172, and CT682 [pbpB])
utilizing a multilocus sequence typing (MLST) approach
[28,29,41,42]. This will include the amplification and se-
quencing [29,43,44] followed by determining MLST type
using C. trachomatisMLST database (mlstdb.bmc.uu.se).DNA sequencing to identify mutation in 23S rRNA gene
Each specimen will be subjected to DNA sequencing (as
described above) of PCR-amplified region of the 23S rRNA
gene flanking the positions 2057 and 2611. Presence of
changes in three locations, A2057G, A2059G and T2611C
(E. coli numbering), will be determined as they are associ-
ated with increased macrolide resistance [45]. The data
arising from this experiment will be correlated with MICs
as described below.
Detection of Y chromosome
A separate swab will be collected each week and placed
in 400 μl of PBS for Y-chromosome detection as evi-
dence of unprotected sexual exposure. Real-time PCR
directed at amplification of a region of the Y chromo-
some targeting SRY (sex determining region Y) will be
conducted [25,26].
Culture
Endocervical specimens collected by speculum examin-
ation will be used for chlamydia culture. The research
nurse will place the swab immediately into culture
medium, store at −80°C, and courier to the laboratory
on dry ice for processing. Chlamydia isolates will be cul-
tured on HEp-2 to propagate each isolate prior to
progressing to MICs. Specimens will be prepared by
vortexing before addition to 20 hour HEp-2 cultures in
antibiotic free DMEM supplemented with 10% serum.
Cultures will be incubated at 37°C, 5% CO2 for 48 hours
and viable infectious chlamydia elementary bodies will
be harvested by mild sonication. A serial dilution of the
specimen cultured onto coverslips in 24 well plates with
20 hr growth 2 × 105 HEp-2 cells to determine the viable
infectious yield [46].
Minimum inhibitory concentration (MIC)
MIC will be conducted by culturing chlamydia on 20 hr
HEp-2 cells. HEp-2 cells will be used for all MIC determi-
nations as they are the most relevant immortalised cell
line (cervical), are widely used, and have previously been
shown to have consistent performance in MIC assays
when compared to other cell lines [35]. Low passage clin-
ical isolates prepared above will be inoculated onto the
HEp-2 cells at 2500 and 5000 IFU per well. Cultures will
be centrifuged for 1 hr (1200 × g) to ensure equal infection
rates. These inoculums will be used as they have previ-
ously been reported to be an appropriate dose to predict
the MCC (minimum chlamydicidal concentration) and are
adequate numbers to accurately assess the inclusions
formed [35]. The antibiotic will be titrated into the
infected cultures at 4 hours after addition of the chlamydia
using a twofold dilution series from 140 g/ml to 0.008 g/ml
(in fresh media with cycloheximide 1 g/ml). Antibiotic will
be freshly prepared as per the manufacturer’s instructions
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inclusions will be determined by methanol fixing the
coverslips at 30 hours and stained to allow clear visual-
isation and counting of the inclusions on the micro-
scope (Chlamydia Cel, Vital diagnostics). The MIC will
be defined as the concentration at which no typical in-
clusions can be seen on the entire coverslip by micros-
copy examination.
Azithromycin absorption
High-vaginal specimens collected by the research
nurse at the day 7 visit will be preserved in 1 ml of
100% methanol and stored at −80°C prior to analysis.
Azithromycin levels are thought to remain well above
the reported MIC for chlamydia for between 10 to 14 days
post-treatment with 1 g dose [30,31]. Azithromycin levels
in high-vaginal material (cells and mucus) will be mea-
sured using a validated liquid chromatography – tan-
dem mass spectrometry method (LC-MS/MS) [47-50].
An azithromycin standard curve will be prepared in
high-vaginal specimens from a separate individual not
exposed to azithromycin, and azithromycin concentra-
tions detected by LC-MS/MS will be normalised to lipid
concentrations [50]. Azithromycin concentrations in
high-vaginal specimens will be normalised to membrane
lipid concentrations and then calculated using the
standard curve.
Immunological markers
Blood specimens will be taken at the recruitment visit
and from all women who return a positive test of cure
test. Serum will be analyzed for chlamydia antibodies titres
against peptide and protein antigens using previously
described methods [51,52].
Chlamydia test results and management
Women will be treated with 1 gram azithromycin
according to site protocol at the time of recruitment.
Those who have a positive test of cure by PCR at day 28,
42 or 56 will be asked to return to the clinic for further
treatment of doxycycline 100 mg twice daily for ten
days. All laboratory assay results will be forwarded to
the study centre and entered into the study database.
Partner notification
At the time of recruitment, the research nurse will explain
the importance of treating sexual partners and avoiding
sexual contact for 7 days. Multiple strategies to support
partner treatment will be explored. Participants will be
given a business card that contains the web address for Let
Them Know (http://www.letthemknow.org.au/), a partner
notification service for sexual contacts of chlamydia and
other STIs. Let them know allows individuals to send a
message to a partner, either anonymously or named, bySMS or email. If preferred, women may direct their part-
ners to call the research nurse for information and a refer-
ral to appropriate clinical care. Women may also consent
to have their sexual partner(s) contacted for a telephone
consultation and, if appropriate, prescribed azithromycin
treatment for partner or mail delivery. This method has
been used in several studies at Melbourne Sexual Health
Centre and has been very effective at maximizing partner
treatment [53,54].
Data collection
Participants will be asked to complete questionnaires at
the time of recruitment and each week until they reach
study endpoint. The following data will be collected:
 Age, height, weight
 Genital symptoms
 Reason for attending clinic for their initial test
 Current medications including contraceptives and
concurrent antibiotics
 Date of last menses
 Sexual practice data including number of sexual
partners, type of sexual partners (casual, occasional,
once off or regular), type of sexual contact (vaginal
or anal sex), condom use; and
 Whether partners have been notified and treated
Data analysis
Sample size estimates
To detect a treatment failure risk of 8% with a 95% CI
of 5.5%, 10.5%, 450 women are required. If the risk of
treatment failure is observed to be 3% (as reported by
the earlier meta-analysis [22]), then a sample size of 450
generates a 95% CI of (1.7%, 5.0%). To account for a loss
to follow up of 15% based on previous studies [8], 520
women will be recruited.
Statistical analysis
The population risk of treatment failure will be estimated
as the observed proportion of women in the sample with
treatment failure, with 95% CI calculated assuming an
underlying binomial distribution. Multinomial logistic re-
gression will be used to explore the association between
the three-level outcome variable (treatment failure, treat-
ment success, re-infection) and risk factors such as the im-
pact of organism load, azithromycin absorption and MIC.
One advantage of a multinominal model over two separate
logistic regression models (one comparing the prevalence
of treatment failure with treatment success, the other
comparing the prevalence of re-infection with treatment
success) is that the question of whether treatment failure
and re-infection share common risk factors can be
addressed formally by comparing estimated odds ratios
generated by the same model. Linear regression analyses
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time and explore any associations with symptoms, chla-
mydia serovar and participant age. Both linear and
multinomial regression models will be implemented
with fixed and random regression effects to accommodate
the longitudinal and repeated measures nature of the data.
All analyses will be conducted in Stata 12.0.
Loss to follow up
The provision of reimbursement payments throughout
the study is paramount to maximize retention. Women
will be reimbursed with vouchers totalling up to $100 to
cover their transport and time costs during the study.
This will be broken down into smaller payments, $25 at
their first follow up visit, $10 for their day 14 specimen,
$10 for their day 21 specimen, $25 for their day 28 speci-
men and then $30 upon completion of the study (day 56
specimen or earlier if repeat positive). Reimbursements
will reflect how many specimens and questionnaires are
returned.
Discussion
Distinguishing between chlamydia re-infection and treat-
ment failure is important to focus treatment recommen-
dations and infection control mechanisms. For example,
if most repeat infections in this study are found to be re-
infections, then strategies to expedite partner treatment
are necessary. If many repeat infections are due to anti-
biotic treatment failure, then international recommenda-
tions on chlamydia treatment need to be re-evaluated.
Previous studies that have reported an azithromycin
treatment failure rate of 2-3% utilized test of cure by
chlamydia culture which, in the last decade, has been re-
placed by more sensitive PCR testing [22]. Chlamydia
treatment studies that have utilized PCR testing have
reported much higher treatment failure rates of up to
8%; however these studies were not designed to reliably
distinguish between re-infections and treatment failure
[10,17]. Our study is one of the first to use both robust
molecular microbiological testing and validated behav-
ioural data so that treatment failure rates can be more
accurately estimated. We hypothesize that the treatment
failure rate will be closer to 8%.
If our hypothesis is correct and 8%, rather than 2-3%,
fail chlamydia treatment with azithromycin, then nearly
3,000 women in Australia and 70,000 women in the
USA were inadequately treated for chlamydia in 2011
[2,55]. Treatment failure will lead to persistent infection
with a longer duration of infection and increased risk of
complications as well as continued transmission in the
population. Further, as chlamydia culture has been rarely
undertaken over the last decade, there is little monitor-
ing of chlamydia antibiotic susceptibility, and the role of
antimicrobial resistance in treatment failure is unknown[35]. The ability to differentiate between re-infection and
treatment failure is a strength of this study. Techniques
used will include measuring azithromycin absorption in
genital cells, chlamydia culture, genotyping, DNA sequen-
cing and antimicrobial sensitivity determinations of the
chlamydia isolates obtained. The results from this study
will inform discussions about chlamydia treatment failure
and help to establish whether 1 gram azithromycin, the
most widely recommended chlamydia treatment inter-
nationally, is appropriate. If treatment failure is confirmed
to be higher than previously estimated, then further chla-
mydia treatment trials to suggest changes to international
treatment guidelines will be indicated.
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